# KPV

> Source: https://peptidestogo.com/peptides/kpv/
> Last updated August 23, 2026 · PeptidesToGo Editorial Team · Educational, not medical advice

α-MSH(11–13) tripeptide

**Status:** Not FDA-approved · no US pharmacy route

**How it is delivered:** Oral · Nasal spray · Gel or cream — no established human protocol.

KPV is a tripeptide — lysine, proline, valine — clipped from the tail end of α-MSH, a hormone your pituitary already makes to regulate pigmentation and inflammation. At three amino acids, it’s about as small as a peptide gets: for scale, BPC-157 is fifteen residues and MOTS-c is sixteen. The interest in KPV comes from a specific finding — it keeps most of the parent hormone’s anti-inflammatory activity while losing the pigment-driving effect entirely.

What makes KPV unusual is *how* it works. It doesn’t use the receptor α-MSH normally binds. Instead, it appears to enter cells through a transporter called PepT1 — one that switches on specifically in tissue that’s already inflamed, particularly gut lining — and dials down inflammatory signaling from inside the cell. That’s a locally-targeted story, most active exactly where inflammation already exists, rather than a peptide that circulates broadly through the bloodstream.

> “KPV may be the most mechanistically well-mapped tripeptide in the pipeline — the open question isn’t how it works, it’s whether it works in people.”

The animal work behind this mechanism is real and has been reproduced across labs. The full pathway detail, every study, and the delivery-route research belong on our PeptideWellness deep-dive.

Last updated August 23, 2026 · PeptidesToGo Editorial Team ·
[Educational, not medical advice](https://peptidestogo.com/legal/medical-disclaimer/)

## Who it's for (or who should avoid)

### What it's aimed at

Right now, KPV is best understood as a research-stage candidate rather than an established protocol. People currently paying attention to it tend to be:

- Those following gut-health and inflammation research closely, including the PepT1 transporter mechanism
- Patients whose providers track the FDA’s compounding-list review pipeline
- People already using better-evidenced recovery peptides who want to understand what’s next in that space
- Clinicians and researchers monitoring transporter-targeted anti-inflammatory approaches generally

KPV works alongside an honest conversation about evidence stage, not instead of one. It isn’t a substitute for treatments with an established human track record, and it shouldn’t be framed as one.

### Who should avoid it

- Anyone expecting established human safety or efficacy data — none exists yet for KPV specifically
- Anyone pregnant, breastfeeding, or trying to conceive — there’s no data in any of these populations
- Anyone who needs a proven treatment now rather than an investigational compound with no completed human trial
- Anyone sourcing from unverified “research use only” vendors instead of discussing options with a licensed provider

## Route, dose and course

**Used for:** Gut-lining and inflammation biology — preclinical only

**How it’s taken:** Not published — No established human dose for any route. It is sold as capsules, creams, sprays and vials under research-use-only labeling, and it is on no 503A list, so no pharmacy can lawfully prepare it.

**What it is:** The C-terminal tripeptide of alpha-MSH — positions 11 to 13, lysine-proline-valine, molecular weight 342.43. A fragment of a hormone the body already makes.

**The mechanism oddity:** It cannot bind any known melanocortin receptor, and the anti-inflammatory effect is reproducible anyway. The route appears to run through PepT1, a transporter upregulated in inflamed gut epithelium — a transporter rather than a receptor, which is unusual and unusually well mapped.

**Human trials:** None. A ClinicalTrials.gov search with no status filter, checked July 28, 2026, returned zero registered trials, and no dedicated human safety or toxicology data exists for KPV itself.

**Where the regulation stands:** The FDA's compounding advisory committee voted 8–6–1 in July 2026 to recommend it for the 503A bulks list — against its own reviewers' recommendation. The vote is non-binding, and it is not on the list.

KPV is currently sold as oral capsules, topical creams, nasal sprays, and occasionally injectable preparations — almost always under research-use-only labeling, since it isn’t yet on the FDA’s list of substances a compounding pharmacy may legally prepare for people. That regulatory gap matters for delivery too: there’s no established human dosing for any of these forms.

What the evidence says about each route:

- **Oral capsules** — widely sold, but no confirmed human bioavailability or pharmacokinetic data exists for any species or route
- **Topical creams** — passive diffusion has been measured at below-detection levels on human skin; meaningful delivery in lab testing required microneedling or iontophoresis, not a cream alone
- **Compounded or injectable forms** — not currently authorized under the standard 503A compounding pathway, so a licensed pharmacy can’t yet prepare it that way
- **Discuss with a clinician** — because there’s no established dosing, safety profile, or delivery method, this is a conversation about whether to wait for more research, not a protocol to begin today

## The usual arc

**Read this first.** This isn't a treatment-response timeline — there's no human trial data yet to build one from. It's an honest picture of where the evidence and the regulation stand, and what would need to happen next.

Because there’s no human trial behind KPV yet, there’s no treatment-response timeline to describe honestly. What can be tracked is the evidence and regulatory picture itself — and it’s moving. Here’s how that’s likely to unfold from here:

**WHERE THINGS STAND NOW Favorable vote, no rule yet** A July 2026 FDA advisory committee voted narrowly in favor of allowing compounding pharmacies to work with KPV. That's a recommendation, not a rule — FDA hasn't acted on it.

**WHAT COMES NEXT Rulemaking, if it happens** Adding KPV to the legal compounding list requires a proposed rule, a public comment period, and a final rule. None of that has started, and there's no published timeline.

**WHAT WOULD CHANGE THE PICTURE A first human study** No registered human trial exists yet. A Phase 1 study, a pharmacokinetic profile, or a final FDA determination would each meaningfully move this forward.

## No provider we've verified carries KPV yet

That is the honest answer, and it is not the same as "you can't have it". None of the
 licensed telehealth providers we track publishes KPV, so there is
 no price to quote and no intake to send you to. Whether that changes depends on federal action rather than on us — which is why the next box
 exists rather than a button that goes nowhere.

### Tell me when someone carries it

### In the meantime

- [Peptides you can get today for the same goal](https://peptidestogo.com/tools/provider-match/)
- [Everything in Recovery & Healing](https://peptidestogo.com/peptides/recovery/)

## Questions we get about KPV

### Is KPV FDA-approved?

No. KPV has never been approved for any indication, anywhere. In July 2026 an FDA advisory committee voted 8-6 with one abstention to recommend it for the list of substances pharmacies may legally compound — but that vote is non-binding, FDA hasn't issued a final rule, and KPV is not currently on that list.

### Is it legal?

It's sold widely under "research use only" labeling, which shifts liability to the buyer rather than authorizing human use — FDA has sent warning letters to sellers whose marketing implies otherwise. Because KPV isn't yet on the legal compounding list, a standard prescription pathway through a compounding pharmacy isn't fully established. A state-by-state check does not apply here: the barrier is federal, and it is the same in all fifty.

### Are there side effects?

There's no human safety data of any kind — no trial, no case report, no tolerability study. What exists is incidental cytocompatibility data from animal and cell-culture work, which hasn't flagged major concerns but doesn't establish human safety either. This is a conversation for a licensed clinician, not a settled answer.

### Can I take it with my current medications?

There's no published interaction data for KPV in humans, so this genuinely isn't known yet. If you're considering it, bring your full medication and supplement list to a clinician who follows the research closely before making any decision.

### How much does it cost?

Pricing on research-grade KPV products varies widely and isn't standardized, since it isn't an FDA-approved or currently-compoundable drug — insurance doesn't apply. Purity and sourcing vary a lot across sellers in this gray-zone market, which is exactly why working with a vetted provider matters more here than for established peptides.

We publish no medical reviewer by design. Every claim on this page traces to a
 source we hold on file, and the reviewed write-up with those citations lives on our
 hub.
[Read the full research on PeptideWellness ↗](https://peptidewellnessusa.com/peptides/kpv/)

## Related peptides